PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
Panelists discuss how PSMA PET imaging utilizes various tracers, each with distinct properties influencing image quality and diagnostic accuracy. Fluciclovine F18 (Axumin) is primarily used for detecting recurrent prostate cancer, offering moderate sensitivity but lower specificity compared with PSMA-targeted agents. Gallium Ga 68 gozetotide (Illuccix) provides high sensitivity and specificity for prostate cancer lesions; however, its shorter half-life and limited availability may restrict widespread use. Piflufolastat F18 (Pylarify) combines the benefits of F18’s longer half-life with high image resolution, enhancing detection accuracy. Similarly, flotufolastat F18 (Posluma) leverages F18’s favorable imaging characteristics, offering high-quality images and reliable lesion detection.
Video content above is prompted by the following:
- Present prostate-specific membrane antigen (PSMA) PET images using the available tracer agents, highlighting key similarities and differences in terms of image quality/resolution and accuracy.
- Axumin (fluciclovine F18)
- Illuccix (gallium Ga 68 gozetotide)
- Pylarify (piflufolastat F18)
- Posluma (flotufolastat F18)
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
